Potential role of immunotherapy for advanced breast cancer

References

• 1. Harbeck N, Penault-Llorca F, Cortes J et al. Breast cancer. Nat. Rev. Dis. Primers. 5(1), 66 (2019).Crossref, Medline, Google Scholar
• 2. Cardoso F, Paluch-Shimon S, Senkus E et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31(12), 1623–1649 (2020).Crossref, Medline, CAS, Google Scholar
• 3. Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer 18(1), 556 (2018).Crossref, Medline, Google Scholar
• 4. Emens L. Breast cancer immunotherapy: facts and hopes. Clin. Cancer Res. 24(3), 511–520 (2018).Crossref, Medline, CAS, Google Scholar
• 5. Basu A, Ramamoorthi G, Jia Y et al. Immunotherapy in breast cancer: current status and future directions. Adv. Cancer Res. 143, 295–349 (2019).Crossref, Medline, Google Scholar
• 6. Basile D, Pelizzari G, Vitale M et al. Atezolizumab for the treatment of breast cancer. Expert Opin. Biol. Ther. 18(5), 595–603 (2018).Crossref, Medline, CAS, Google Scholar
• 7. Esteva F, Hubbard-Lucey V, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20(3), 175–186 (2019).Crossref, Medline, CAS, Google Scholar
• 8. Cortes J, Cescon D, Rugo H et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomized, placebo-controlled, double-blind, Phase III clinical trial. Lancet 10265(396), 1817–1828 (2020).Crossref, Google Scholar
• 9. Kyte J, Andresen N, Russnes H et al. ICON: a randomized Phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. J. Transl. Med. 18(1), 269 (2020).Crossref, Medline, CAS, Google Scholar
• 10. Bajgain P, Tawinwung S, D'Elia L et al. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J. Immunother. Cancer 6(1), 34 (2018).Crossref, Medline, Google Scholar
• 11. Tchou J, Zhao Y, Levine B et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (car) t cells in metastatic breast cancer. Cancer Immunol. Res. 5(12), 1152–1161 (2017).Crossref, Medline, CAS, Google Scholar
• 12. Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine therapies for breast cancer. Surg. Oncol. Clin. N. Am. 28(3), 353–367 (2019).Crossref, Medline, Google Scholar
• 13. Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 37(12), 855–865 (2016).Crossref, Medline, CAS, Google Scholar
• 14. Abdellateif M, Shaarawy S, Kandeel E, El-Habashy A, Salem M, El-Houseini M. A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine. Oncol. Lett. 16(1), 529–535 (2018).Medline, Google Scholar
• 15. Tang M, Liu Y, Zhang QC et al. Antitumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro. Oncol. Lett. 16(3), 2813–2822 (2018).Medline, Google Scholar
• 16. Arab A, Behravan N, Razazn A et al. The viral approach to breast cancer immunotherapy. J. Cell. Physiol. 234(2), 1257–1267 (2019).Crossref, Medline, CAS, Google Scholar
• 17. Guo ZS, Lu B, Guo Z et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J. Immunother. Cancer 7(1), 6 (2019).Crossref, Medline, CAS, Google Scholar